Publications

Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

 92
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH

Tags:

Previous Article

Human Schwann cell lipid dysregulation and plasma membrane perturbation in Charc...

Next Article

FerroTerminator1 as a potent therapeutic drug for MASH

Related Posts

Maternal circadian rhythms during pregnancy dictate metabolic plasticity in offspring

Maternal circadian rhythms during pregnancy dictate met...

 83

Increased cholesterol synthesis drives neurotoxicity in patient stem cell-derived model of multiple sclerosis

Increased cholesterol synthesis drives neurotoxicity in...

 104

The interoceptive origin of reinforcement learning

The interoceptive origin of reinforcement learning

 140